Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 by Matthew Wood et al. covering cell-penetrating peptides with dual hydrophobic domains for treating genetic disorders, specifically Duchenne muscular dystrophy. The application (filed October 21, 2025) discloses peptide compositions and conjugates with therapeutic molecules. This is a publication of a pending application and does not yet grant enforceable patent rights.

ASXL1 Disruption in T Cells for Immunotherapy Enhancement

The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.

Biallelic Knockout of CTLA4

The USPTO published patent application US20260091113A1 by inventor Rafi Emmanuel covering compositions and methods for biallelic knockout of CTLA4 using RNA guide sequences. The application includes 4,891 sequence variants (SEQ ID NOs: 1-4891) with potential therapeutic applications. Filed September 18, 2023; published April 2, 2026.

Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen

USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.

Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.